Predictive Genetic Testing and Consumer Genomics Market - By Test Type, By Application, By Setting– Global Forecast, 2025 – 2034

Predictive Genetic Testing and Consumer Genomics Market Size

The global predictive genetic testing and consumer genomics market size was estimated at USD 7.4 billion in 2024. The market is expected to grow from USD 8.3 billion in 2025 to USD 27.1 billion in 2034, at a CAGR of 14% during the forecast period. This growth is fueled by increasing consumer attention concerning personalized healthcare, technology developments in genetic testing, and a shift toward proactive preventative healthcare.
 

National Center for Biotechnology Information (NCBI) reports that the number of new genetic tests rose from 1,081 in 2012 to 6,214 in 2022. Such trends are bolstering the growth of the market as people look for tailored healthcare services to address the health challenges posed by their genetic makeup.
 

Moreover, with the rise of direct-to-consumer (DTC) genetic testing, consumer genomics is enabling people to investigate their ancestry, lifestyle traits, and potential health predispositions more easily than ever before. Accuracy, affordability, and accessibility are heightened by ongoing advancements in next generation sequencing (NGS) technologies and AI-driven genomic analysis. In addition, partnerships between genetic testing firms and healthcare institutions are further advancing the predictive value of genetic testing through the integration of genomic information into individualized treatment design frameworks, thereby driving market growth.
 

The market includes tools and services that analyze genetic information to anticipate lifestyle traits, ancestry, and even health issues of an individual. The market is directed towards healthcare providers and consumers, focusing on primary care enhancement, wellness advancement, and optimizing drug responses, which enables genomic information to be integrated into personalized healthcare frameworks.
 

Predictive Genetic Testing and Consumer Genomics Market Trends

• The rapid advancements in genomic technologies, coupled with decreasing sequencing costs and growing public awareness of genetics and their impact on health, ancestry, and heritage, are driving the expansion of the market. These factors are making genetic insights more accessible and appealing to a broader consumer base, further fueling market growth.
   
• The widespread availability of direct-to-consumer (DTC) testing kits is allowing the public to comprehend their susceptibility to various health issues, thus increasing market demand.
   
• Predictive testing is becoming more popular due to the increase in chronic and hereditary diseases. According to the WHO, 17.9 million people die every year from CVD and nearly 9–10 million die from cancer. Predictive testing can flag certain cancer risks early, such as mutations of the BRCA gene which are linked with breast cancer.
   
• The field of personal genomics has already evolved in the last decade due to the fact that more than 30 million people globally showed interest in direct-to-consumer genetic tests offering ancestry, traits, and even health predisposition information. Consumer genomics is now a feature of wellness apps and digital platforms that aid in health optimization.
   
• The development of nutrigenomics and pharmacogenomics is providing customized recommendations for lifestyle and treatment. The National Institutes of Health states that 80% of adverse drug reactions have a genetic basis which makes genetic profiling important in determining personalized prescriptions.
   
• Advances in next-generation sequencing (NGS) technologies have brought the price of sequencing the human genome down. As stated by the World Intellectual Property Organization (WIPO), the cost of genome sequencing has significantly decreased from USD 100 million in 2001 to approximately USD 500 in 2023, enabling mass-scale testing. The combination of microarray technologies with AI diagnostics is also improving the availability and speed of testing.
   
• Moreover, government initiatives are fueling the predictive genetic testing and consumer genomics market growth. For example, the UK’s 100,000 Genomes Project completed whole-genome sequencing of over 100,000 NHS patients by 2022. Also, the U.S. NIH’s All of Us Research Program aims to gather data from over 1 million participants.
   
• Further, there are over 150 startups and international corporations competing in multi-omics, consumer apps, and wearable integrations. This competition enhances dashboards, health tracking devices, and tailored wellness analytics, which are turning consumer genomics into a vital part of the digital head ecosystem.
   

Trump Administration Tariffs

• The latest developments in global trade policies such as monitoring imports in biotechnology and controlling the export of genomic data are starting to impact on the cost and flexibility of business operations within the predictive genetic testing and consumer genomics industry. Limitations on the flow of information, particularly between the U.S., China, and the EU, are creating compliance difficulties for firms that operate on a global scale and collect and analyze genetic data.
   
• This will cause several companies in the genomics market to consider realigning their localization strategies to comply with the EU’s General Data Protection Regulation (GDPR) and China's Personal Information Protection Law (PIPL). This will further led to growing investment in domestic sequencing facilities and regional cloud infrastructure to ensure legal conformity and uninterrupted services.
   
• In the short term, these imposed changes and trade policies will increase the cost of business operations, with stunted international scaling, and the need for customized regulatory strategies by region.
   
• Additionally, increased governmental restrictions focused on data sovereignty and biosecurity have required these companies to implement strict data governance policies, thus forcing firms to increase spending for compliance-centric technologies and alliances.
   

Predictive Genetic Testing and Consumer Genomics Market Analysis

Based on test type, the market is segmented into predictive testing, consumer genomics, and wellness genomics. The predictive testing segment dominated the market with USD 4.1 billion in 2024.
 

• Predictive testing is a type of genetic body mapping that evaluates the likelihood of a person developing certain diseases or disorders considering his or her ancestry. This test looks for unique genetic changes that may cause a person to contract cancer, heart conditions, or neurodegenerative disorders.
   
• Predictive medicine focuses on preventing diseases by providing early intervention, lifestyle changes, and effective tailored healthcare reducing highly individualized risks.
   
• Additionally, newer discoveries in genomics and biotechnology are making the process of predictive testing simpler and more precise. Predictive genetic testing offers customized genetic information, which profoundly impacts individual healthcare, thus bolstering the market.
   

Based on application, the predictive genetic testing and consumer genomics market is divided into cancer screening, cardiovascular screening, musculoskeletal screening, diabetic screening and monitoring, Parkinson’s / Alzheimer disease screening, and other applications. The cancer screening segment accounted for significant market share of 33.1% in 2024.
 

• The cancer screening segment is a vital application within the market. It uses the genetic examination of various inherited cancers to detect mutations in genes such as BRCA1 and BRCA2, which are associated with breast, ovarian, and colorectal cancer.
   
• As it pertains to prompt diagnosis, specific risk evaluation, and action-oriented prevention, this method enables individuals to take informed actions.
   
• In addition, consumer genomics has made cancer screening more accessible by providing tests without healthcare professionals referrals that encourage better management of individual health.
   

Based on setting, the predictive genetic testing and consumer genomics market is divided into direct-to-consumer (DTC), hospitals and clinics, and diagnostic laboratories. The direct-to-consumer (DTC) segment dominated the market with USD 4.3 billion in 2024 and expected to reach USD 14.5 billion within the forecast period.  
 

• The DTC segment within predictive genetic testing and consumer genomics has emerged as a pivotal market driver. It enables consumers to obtain genetic information directly, without medical intermediaries, promoting personalized health management. This segment focuses on catering to lifestyle, ancestry, and health risks using advanced genomic technologies.
   
• Businesses in this industry provide intuitive and inexpensive testing platforms and kits, promoting utilization and acceptance worldwide. The DTC market is growing despite struggles with ethics and privacy because of increasing interest in preventive marketing and precision medicine.
   
• Further, strategic marketing and big data analytics also help to empower consumers to make better health choices.
   

The North America predictive genetic testing and consumer genomics market held the largest market share of 42% in 2024 in the global market, and it is anticipated to expand at 13.9% CAGR over the forecast period. The U.S. market was valued at USD 2.5 billion in 2023.
 

• The U.S. is one of the largest markets for predictive genetic testing and consumer genomics due to an established healthcare system and high acceptance of personalized medicine. A large population of informed consumers and the availability of DTC genetic tests have increased the demand.
   
• In addition, other government support for genomics research such as NIH funded projects, alongside the adoption of pharmacogenomics in clinical settings, fuels market growth.
   
• Moreover, leading market players provide innovative ancestry, health risk, and wellness assessments which expand the market. The growing burden of chronic disease among an increasingly tech-savvy population drives sustained expansion, through greater collaboration between genetic testing companies and healthcare providers wherein genomic medicine becomes clinically applicable.
   

The Germany predictive genetic testing and consumer genomics market is experiencing robust growth in Europe market.  
 

• Germany has a well-defined market for predictive genetic testing and consumer genomics due to its well-developed healthcare infrastructure and focus on biotechnology. This is fueled by the country’s growth in precision medicine and the rising consumer spending on preventive healthcare.
   
• Increased spending on research and supportive legal frameworks encourage innovations in genetic diagnostics and pharmacogenomics. The increasing prevalence of age-related illnesses and hereditary disorders has made the need for genetic tests rise.
   
• Additionally, collaborations between academic institutions and private companies are enhancing test development and accessibility, positioning Germany as a significant contributor to the genomic healthcare revolution.
   

The Asia Pacific predictive genetic testing and consumer genomics market is witnessing substantial growth of 14.3% during the analysis period.
 

• The growth of China’s market is being fueled by the increasing middle class, heightened awareness of healthcare, and government spending on genomic research.
   
• Marketing for genomic medicine has been aided by policies such as the Precision Medicine Initiative. The refinement of next generation sequencing technologies has sparked massive demand for ancestry testing, wellness insight, and predisposition screening.
   
• In addition, local companies are developing new solutions for the technologically inclined population, while foreign companies are entering the market through collaborations.
   
• Moreover, China’s enormous and diverse population serves as a great asset for the development of genomic solutions, facilitating market expansion.
   

The Brazil predictive genetic testing and consumer genomics market is experiencing robust growth in Latin America market.
 

• Brazil's market is steadily growing on account of increased personalized healthcare services and ancestry testing. The diverse population of the country is becoming more interested in understanding genetic ancestry, causing awareness of hereditary health risks increasing the uptake of predictive testing.
   
• Genetic diagnostics are becoming more accessible due to government healthcare reforms and investments in biotechnology. Stronger spending on wellness solutions among the growing middle class is complemented by collaborations between local research institutions and foreign companies, which are driving innovation.
   

The Saudi Arabia predictive genetic testing and consumer genomics market is witnessing substantial growth during the analysis period.
 

• Saudi Arabia's market is gaining momentum, fueled by government initiatives to modernize healthcare and prioritize precision medicine.
   
• Additionally, the high prevalence of genetic disorders due to consanguineous marriages has driven demand for predictive testing. The Saudi Vision 2030 plan emphasizes biotechnology and personalized medicine, supporting investments in genomic research and infrastructure.
   
• Moreover, the growing public interest in ancestry, wellness testing, and advanced genetic diagnostics drives the market further.
   
• Alongside, increased partnerships and collaborations with international genomics companies and research institutions strengthens Saudi Arabia's market.
   

Predictive Genetic Testing and Consumer Genomics Market Share

The top 5 companies in the market, such as Illumina, Thermo Fisher Scientific, Myriad Genetics, QIAGEN, and Abbott, account for approximately 65% of the global market share. These companies maintain their leadership through continuous innovation in sequencing platforms, bioinformatics pipelines, and clinical-grade genetic testing services, meeting growing demand for precision medicine and consumer-driven health insights.
 

Market leaders are expanding their offerings with whole-genome and exome sequencing, advanced diagnostic assays, and AI-enabled interpretation tools for actionable genetic insights. For instance, Illumina and Thermo Fisher focus on scalable NGS solutions and automated platforms for clinical use, while Myriad Genetics and QIAGEN provide comprehensive hereditary cancer panels and companion diagnostics. The intensifying competition, supported by AI, big data integration, and regulatory-aligned platforms, is accelerating growth and reshaping global genomics ecosystems.
 

Predictive Genetic Testing and Consumer Genomics Market Companies

Major players operating in the predictive genetic testing and consumer genomics industry are:

• Abbott Laboratories
• Agilent Technologies
• ARUP Laboratories
• BGI Genomics
• Bio-Rad Laboratories
• Danaher
• EasyDNA
• F. Hoffmann-La Roche
• Illumina
• Myriad Genetics
• QIAGEN
• Quest Diagnostics
• Thermo Fisher Scientific
• Variantyx
   
• Abbott Laboratories specializes in cutting-edge diagnostic solutions, including their FreeStyle Libre system, which enables continuous glucose monitoring through advanced genetic and metabolic insights. Their offerings enhance personalized healthcare, providing patients and healthcare providers with critical data for proactive disease management.
   
• ARUP Laboratories offers a comprehensive range of genetic tests, including their Carrier Screening Test, which helps assess genetic risks for inherited conditions. This service supports informed reproductive decisions by identifying potential genetic disorders early, contributing to better long-term health management.
   
• Bio-Rad Laboratories offers advanced genetic analysis tools, including their Droplet Digital PCR (ddPCR) Technology, which is used for precise genetic mutation detection in rare diseases. Their products enable faster, more accurate diagnostics for a wide range of conditions, empowering healthcare providers to deliver personalized treatment plans.
   

Predictive Genetic Testing and Consumer Genomics Industry News

• In April 2025, Illumina partnered with Tempus to advance precision medicine by combining genomic insights with AI innovation. This collaboration aims to enhance predictive genetic testing and accelerate the development of personalized healthcare solutions in the consumer genomics market.
   
• In August 2024, Myriad Genetics, in collaboration with Eurobio Scientific, launched the EndoPredict prognostic test to assess breast cancer recurrence risk, helping patients make informed treatment decisions and potentially avoid unnecessary chemotherapy.
   
• In August 2024, Genetic Technologies globally launched its geneType multi-risk predictive genetic testing on the wholly owned EasyDNA platform, expanding access to personalized health insights and risk assessment in the market.
   
• In August 2024, Illumina received FDA approval for its TruSight Oncology (TSO) Comprehensive test, a pan-cancer companion diagnostic that enables broad genomic profiling of solid tumors advancing precision medicine and supporting predictive genetic testing in oncology through a distributable IVD kit.
   
• In January 2024, Danaher, Jennifer Doudna, and the Innovative Genomics Institute launched the Danaher-IGI Beacon for CRISPR Cures, aiming to advance gene-editing solutions. The initiative seeks to address numerous diseases, fostering innovation in predictive genetic testing and consumer genomics.
   
• In January 2024, Blueprint Genetics, a subsidiary of Quest Diagnostics, introduced six new reproductive carrier screening tests, including FMR1 repeat expansion analysis, enhancing genetic testing options for identifying inherited conditions and supporting informed family planning in the market.
   

The predictive genetic testing and consumer genomics market research report include in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Predictive testing
  • Genetic susceptibility test
  • Predictive diagnostics
  • Population screening
• Consumer genomics
• Wellness genomics
  • Nutria genetics
  • Skin and metabolism genetics
  • Other wellness genomics

Market, By Application

• Cancer screening
• Cardiovascular screening
• Musculoskeletal screening
• Diabetic screening and monitoring
• Parkinsons/Alzheimer disease screening
• Other applications

Market, By Setting

• Direct-to-consumer (DTC)
• Hospitals and clinics
• Diagnostic laboratories

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE